Intuitive Surgical's stock plunged to a 52-week low after reaffirming 2026 growth outlook but flagging slowing U.S. procedure trends due to deferred procedures and insurance issues, alongside increased competition and policy pressures in China. This news led to significant analyst price target cuts, indicating a material shift in short-term investor sentiment and valuation expectations.
Intuitive Surgical (ISRG) experienced a sharp decline in its stock price due to several converging headwinds. The company reported a moderation in U.S. procedure growth, particularly for deferrable procedures, and cited the expiration of ACA premium subsidies as a contributing factor. Internationally, increased domestic competition and policy-driven pricing pressure in China, along with a challenging operating environment, are significant concerns. While the long-term outlook remains positive for some analysts, the immediate impact is a re-evaluation of the company's near-term growth trajectory and profitability, leading to widespread analyst price target reductions and a significant drop in market capitalization. Traders face short-term downside risk due to these revised expectations and competitive pressures.